Berry Genomics Co.,Ltd

Symbol: 000710.SZ

SHZ

9.49

CNY

Market price today

  • -8.2294

    P/E Ratio

  • 0.1034

    PEG Ratio

  • 3.34B

    MRK Cap

  • 0.00%

    DIV Yield

Berry Genomics Co.,Ltd (000710-SZ) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.47%

Operating Profit Margin

-0.36%

Net Profit Margin

-0.35%

Return on Assets

-0.15%

Return on Equity

-0.20%

Return on Capital Employed

-0.21%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Yang Gao
Full-time employees:1438
City:Beijing
Address:Building 5
IPO:1997-04-22
CIK:

Berry Genomics Co.,Ltd, a genomics company, develops and commercializes technologies for the life sciences and clinical applications in China. The company offers NGS- based tests for various genetic diseases and cancers from preconception to adulthood; WES test for inherited pathogenic mutations in the GCH1 gene associated with the metabolic disease Dopa-responsive dystonia; CNV-Seq test for indicating translocation at the end of chromosomes 2 and 8; RNA-Seq test to demonstrate the photo-induced protein dimerization of plant cryptochromes; and WGS test for genome wide detection of DNA variants, including SNP, CNV, Indel, and SV. It serves approximately 2,000 hospitals throughout Mainland China, Hong Kong, Macao, and Taiwan. The company serves various organizations and facilities, including hospitals, research institutions, universities, and corporations. Berry Genomics Co.,Ltd has a partnership with Personalis, Inc. The company was founded in 2010 and is headquartered in Beijing, China.

General Outlook

When we look at how much money they make before expenses, they keep 0.465% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.359%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.347%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.148% return, is a testament to Berry Genomics Co.,Ltd's adeptness in optimizing resource deployment. Berry Genomics Co.,Ltd's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.196%. Furthermore, the proficiency of Berry Genomics Co.,Ltd in capital utilization is underscored by a remarkable -0.208% return on capital employed.

Stock Prices

Berry Genomics Co.,Ltd's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $9.82, while its low point bottomed out at $9.45. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Berry Genomics Co.,Ltd's stock market.

Liquidity Ratios

Analyzing 000710.SZ liquidity ratios reveals its financial health of the firm. The current ratio of 202.34% gauges short-term asset coverage for liabilities. The quick ratio (162.84%) assesses immediate liquidity, while the cash ratio (34.60%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio202.34%
Quick Ratio162.84%
Cash Ratio34.60%

Profitability Ratios

000710.SZ profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -36.75% underscores its earnings before tax deductions. The effective tax rate stands at 6.25%, revealing its tax efficiency. The net income per EBT, 94.34%, and the EBT per EBIT, 102.40%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -35.88%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-36.75%
Effective Tax Rate6.25%
Net Income per EBT94.34%
EBT per EBIT102.40%
EBIT per Revenue-35.88%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.02, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding163
Days of Inventory Outstanding122
Operating Cycle408.52
Days of Payables Outstanding156
Cash Conversion Cycle252
Receivables Turnover1.27
Payables Turnover2.33
Inventory Turnover3.00
Fixed Asset Turnover1.26
Asset Turnover0.43

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.31, and free cash flow per share, 0.14, depict cash generation on a per-share basis. The cash per share value, 0.73, showcases liquidity position. A payout ratio of -0.04 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.10, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share0.31
Free Cash Flow per Share0.14
Cash per Share0.73
Payout Ratio-0.04
Operating Cash Flow Sales Ratio0.10
Free Cash Flow to Operating Cash Flow Ratio0.45
Cash Flow Coverage Ratio0.40
Short Term Coverage Ratio0.47
Capital Expenditure Coverage Ratio1.80
Dividend Paid and Capex Coverage Ratio1.45

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 10.25%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.15, we discern the balance between debt and equity financing. The long-term debt to capitalization, 2.20%, and total debt to capitalization, 12.87%, ratios shed light on its capital structure. An interest coverage of -37.97 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio10.25%
Debt Equity Ratio0.15
Long Term Debt to Capitalization2.20%
Total Debt to Capitalization12.87%
Interest Coverage-37.97
Cash Flow to Debt Ratio0.40
Company Equity Multiplier1.44

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 3.26, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1.21, reflects the portion of profit attributed to each share. The book value per share, 5.28, represents the net asset value distributed per share, while the tangible book value per share, 5.07, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share3.26
Net Income Per Share-1.21
Book Value Per Share5.28
Tangible Book Value Per Share5.07
Shareholders Equity Per Share5.28
Interest Debt Per Share0.91
Capex Per Share-0.16

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -15.83%, indicates top-line expansion, while the gross profit growth, -11.84%, reveals profitability trends. EBIT growth, -1839.13%, and operating income growth, -1839.13%, offer insights into operational profitability progression. The net income growth, -69.35%, showcases bottom-line expansion, and the EPS growth, -70.42%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-15.83%
Gross Profit Growth-11.84%
EBIT Growth-1839.13%
Operating Income Growth-1839.13%
Net Income Growth-69.35%
EPS Growth-70.42%
EPS Diluted Growth-70.42%
Weighted Average Shares Growth-0.13%
Weighted Average Shares Diluted Growth-0.13%
Dividends per Share Growth-45.14%
Operating Cash Flow Growth424.14%
Free Cash Flow Growth207.24%
10-Year Revenue Growth per Share86.76%
5-Year Revenue Growth per Share-20.10%
3-Year Revenue Growth per Share-25.75%
10-Year Operating CF Growth per Share202.12%
5-Year Operating CF Growth per Share-32.92%
3-Year Operating CF Growth per Share-31.64%
10-Year Net Income Growth per Share-2851.22%
5-Year Net Income Growth per Share-259.21%
3-Year Net Income Growth per Share-301.43%
10-Year Shareholders Equity Growth per Share586.81%
5-Year Shareholders Equity Growth per Share-2.15%
3-Year Shareholders Equity Growth per Share-22.48%
10-Year Dividend per Share Growth per Share2.28%
5-Year Dividend per Share Growth per Share1930.72%
3-Year Dividend per Share Growth per Share-47.30%
Receivables Growth-25.49%
Inventory Growth-0.71%
Asset Growth-14.36%
Book Value per Share Growth-18.90%
Debt Growth-12.81%
R&D Expense Growth3.07%
SGA Expenses Growth-2.36%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 3,969,070,983.76, captures the company's total value, considering both debt and equity. Income quality, -0.26, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.02, gauges operational efficiency, while the research and development to revenue, 9.55%, highlights investment in innovation. The ratio of intangibles to total assets, 3.79%, indicates the value of non-physical assets, and capex to operating cash flow, -49.64%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value3,969,070,983.76
Income Quality-0.26
Sales General and Administrative to Revenue0.02
Research and Development to Revenue9.55%
Intangibles to Total Assets3.79%
Capex to Operating Cash Flow-49.64%
Capex to Revenue-4.79%
Capex to Depreciation-48.36%
Graham Number11.99
Return on Tangible Assets-16.20%
Graham Net Net0.68
Working Capital709,904,957
Tangible Asset Value1,790,637,664
Net Current Asset Value626,432,836
Average Receivables970,146,210
Average Payables285,693,170
Average Inventory230,125,536.5
Days Sales Outstanding263
Days Payables Outstanding168
Days of Inventory On Hand132
ROIC-19.50%
ROE-0.23%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.75, and the price to book ratio, 1.75, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.85, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 67.01, and price to operating cash flows, 29.84, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.75
Price to Book Ratio1.75
Price to Sales Ratio2.85
Price Cash Flow Ratio29.84
Price Earnings to Growth Ratio0.10
Enterprise Value Multiple-87.56
Price Fair Value1.75
Price to Operating Cash Flow Ratio29.84
Price to Free Cash Flows Ratio67.01
Price to Tangible Book Ratio2.15
Enterprise Value to Sales3.45
Enterprise Value Over EBITDA106.28
EV to Operating Cash Flow35.76
Earnings Yield-10.67%
Free Cash Flow Yield1.40%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Berry Genomics Co.,Ltd (000710.SZ) on the SHZ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -8.229 in 2024.

What is the ticker symbol of Berry Genomics Co.,Ltd stock?

The ticker symbol of Berry Genomics Co.,Ltd stock is 000710.SZ.

What is company IPO date?

IPO date of Berry Genomics Co.,Ltd is 1997-04-22.

What is company current share price?

Current share price is 9.490 CNY.

What is stock market cap today?

The market cap of stock today is 3344623334.000.

What is PEG ratio in 2024?

The current 0.103 is 0.103 in 2024.

What is the number of employees in 2024?

In 2024 the company has 1438.